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Abstract
Although the risk of transfusion-transmitted infections today is lower than ever, the supply of safe
blood products remains subject to contamination with known and yet to be identified human
pathogens. Only continuous improvement and implementation of donor selection, sensitive
screening tests and effective inactivation procedures can ensure the elimination, or at least
reduction, of the risk of acquiring transfusion transmitted infections. In addition, ongoing education
and up-to-date information regarding infectious agents that are potentially transmitted via blood
components is necessary to promote the reporting of adverse events, an important component of
transfusion transmitted disease surveillance. Thus, the collaboration of all parties involved in
transfusion medicine, including national haemovigilance systems, is crucial for protecting a secure
blood product supply from known and emerging blood-borne pathogens.
Background
Although there are early reports in the history of medicine
that describe attempts to treat patients with human or ani-
mal blood products, transfusion medicine is a relatively
young field that has developed only since the second half
of the last century. Very rapidly, however, it became clear
that these therapeutic approaches also carried their prob-
lems, such as the (in-)compatibility of red blood cells and
plasma between donors and recipients, and the possibility
of transmitting infectious diseases [1,2]. While in the past,
the risk of transfusion-transmitted infections (TTI) was
accepted by patients and physicians as unavoidable, a
low-risk blood supply is expected today. Since the early
nineteen sixties, blood banks, as well as plasma manufac-
turing industries, have aggressively pursued strategies to
reduce the risks of TTI. In particular, donor exclusion cri-
teria, such as a history of hepatitis or transfusions in the
past six months have been in place since early on. Today,
donor evaluation, laboratory screening tests and patho-
gen inactivation procedures are considered crucial tools to
reduce the risk of TTI, but do not completely eliminate all
risk. At the same time these advances have moved transfu-
sion medicine towards increasingly safer products, at
steadily escalating costs and thus leading to major differ-
ences in transfusion product safety between wealthy and
poor countries.
The current efforts and strategies have greatly helped
reduce transfusion-associated risks. Indeed, the risk of
being infected by a contaminated blood unit today is
orders of magnitude lower when compared to thirty years
ago (Table 1). A considerable portion of this improve-
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ment is due to the introduction of nucleic acid testing
(NAT), rather than relying solely on measuring pathogen-
specific humoral immune responses in the donor [3]. In
order to maintain the integrity, purity and adequacy of the
blood supply new donor screening assays, donor deferral
and pathogen inactivation of blood components need to
be balanced against the undue loss of potential donors
because of overly stringent exclusion criteria. These efforts
would ideally be supported by national and international
haemovigilance networks that help identify emerging new
TTI threats; by facilitating quality assurance, quality con-
trol and the ability to monitor all steps in the transfusion
chain (Figure 1) [4-6].
Bacterial infections
The risk of bacterial infection has emerged as the major
cause of transfusion related morbidity and mortality, in
part due to the reduction of other risks [4,7-10]. Bacterial
contamination is more frequent in platelet concentrates
(PLT) than in red blood components most likely because
many microorganisms can survive and propagate under
the storage conditions typically used for PLT (20–24°C),
but less so for RBC (1–6°C) [8-11]
As a consequence of the increasing awareness and clinical
relevance of bacterial contamination of blood compo-
nents, the AABB (formerly The American Association of
Blood Banks) released standards to diminish bacterial TTI
[12] in 2004. In particular, bacterial testing of platelets
was suggested as an effective measure to improve transfu-
sion safety. Three testing systems are licensed in the U.S.
and are in use in many transfusion centers around the
world. These screening tests appear quite effective and
recent data indicate that the frequency of bacterial con-
tamination has declined by about 50% or more with con-
tamination being detected in about one in 5,000
apheresis PLT concentrates tested[13]. The estimated inci-
dence rates of bacterial TTI with clinical consequences
range from one in 70,000 to 118,000 transfused PLT,
largely depending on the amount of bacteria transfused
and the type of bacterium and its pathogenicity [13,8,14].
In order to design effective strategies to reduce bacterial
TTI, the bacterial infections are frequently divided based
on the origin of the microorganisms: differentiating infec-
tions that originate from the environment, from the skin
of the transfused subject, or from those that are likely
derived from a donor bacteremia. Most commonly, con-
tamination occurs during blood collection (insufficient
disinfection of venipuncture site), or during handling of
blood products (leaky seals) [15]. As a result, the most
predominant bacteria isolated are usually commensals of
the skin or gastrointestinal tract flora. A report from the
American Red Cross on detection of bacterial contamina-
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Strategies to reduce risk of transfusion transmitted infections.
Donor eligibility
•Careful donor selection lowers risk of dispensing blood products obtained during window period
Screening tests
•Bacterial detection methods for platelets may detect most contaminated units
• NAT testing combined with serology for viral infection decreases the residual risk
Processing, quality control
•Improved donor skin disinfection and diversion of the first 30ml of blood effectively reduces contamination
• Audits and quality control assessments of the procedures during product processing ensures highest safety standards 
Storage, pathogen inactivation
•Optimize storage temperature and time 
• Effective pathogen inactivation procedures that do not compromise product integrity
Indication for transfusion
•Assess the need for each individual transfusion
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tion in platelets showed that the majority of isolates were
Gram-positive aerobic pathogens (nearly 75%), in line
with the organisms identified in platelet units implicated
in cases of transfusion-associated sepsis (56% Gram-posi-
tive aerobes) [7].
Measures to reduce the risk of bacterial contamination
focus on different steps in the transfusion chain (Figure 1)
and can be classified into six aspects:
1.) Donor eligibility: To reduce asymptomatic donor bac-
teremia, subjects with recent dental treatments, minor sur-
gery or increased body temperature at presentation should
be excluded from donation.
2.) Optimal product processing, handling and storage:
Continuous training and supervision of the responsible
personnel for donation and product processing are key
elements for high quality standards and product safety.
Also, consistent storage temperatures (4°C for RBC and
22–24°C for PLT) need to be maintained to ensure prod-
uct integrity.
3.) Skin preparation: Improved donor arm disinfection
has been shown to be crucial in reducing the numbers of
remaining bacteria on the phlebotomy puncture site [16-
18].
4.) Removal of the initial whole blood collection (diver-
sion): It has been shown that removal of the first 30–40
ml of whole blood from the collection bag might reduce
the contamination risk from skin bacteria. In fact,
improved donor arm disinfection in association with
blood diversion has been reported to reduce the risk of
bacterial contamination by up to 77% [19-21].
5.) Bacterial detection methods: Different methods have
been investigated for detecting bacteria in platelet prod-
ucts prior to transfusion, including an automated bacte-
rial culture method (BacT/ALERT system, bioMérieux),
direct bacterial staining, bacterial endotoxin and ribos-
omal assays, nucleic acids testing for bacterial DNA, and
measures of O2 consumption or CO2 production (Pall
BDS, Pall Corporation) [22-25]. However, none of these
detection methods seems to identify all bacterial contam-
inations and additional bacterial screening tests as well as
better timing of bacterial testing (i.e. closer to the time of
transfusion) might be needed to further improve the like-
lihood of correctly identifying bacterially contaminated
blood products.
6.) Pathogen reduction methods: Pathogen reduction is a
pro-active approach to further reduce the risk of TTI and
could prove effective for most known and emerging path-
ogens. The goal of pathogen inactivation is to reduce
transmissible pathogens (bacteria, viruses and protozoa)
without compromising therapeutic efficacy of the blood
product or introducing secondary risks. These techniques
and their current limitations are discussed in more detail
below.
Transfusion-transmitted viral infections
Over the two last decades, much attention has been given
to the prevention of transfusion-transmitted viral infec-
tions such as HIV-1 and -2, human T cell lymphotropic
virus (HTLV) I and II, hepatitis C virus (HCV), hepatitis B
virus (HBV) and West Nile Virus (WNV). Given the poten-
tial transmission of viruses during the 'immunological
window period' [i.e. the period of early infectivity when
an immunologic test is non-reactive], novel non-serology
based approaches such as viral nucleic acid testing (NAT)
have been established. Today NAT is performed on min-
ipools of plasma from 16–24 donations and has signifi-
cantly increased the sensitivity to detect infected blood
components as it reveals viral agents earlier in the 'win-
dow period' than antibody or antigen assays[26]. How-
Table 1: Relative Risk of the most frequent TTI
Risk factor/infectious agent Risk of TTI in blood products released Ref.
U.S. Europe
Virus
HIV 1 in 2,135,000 1 in 909,000 – 5,500,000 26, 30, 33
HCV 1 in 1,930,000 1 in 2,00,000 – 4,400,000 26, 30, 33
HBV 1 in 277,000 1 in 72,000 – 1,100,000* 33
WNV 1 in 350,000 No reported cases 56, 63
HTLV-II 1 in 2,993,000 Not tested 30
Bacteria
Bacterial contamination RBC 1 in 38,500 8, 10
Platelets 1 in 5,000 13
Parasites
Malaria 1 in 1,000,000 – 5,000,000 105
* High variations between low-endemic areas and intermediate-endemic areasJournal of Translational Medicine 2007, 5:25 http://www.translational-medicine.com/content/5/1/25
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ever, it has some limitations in blood components with
very low levels of viremia, which can even escape detec-
tion by NAT [27]. Despite this limitation, the combina-
tion of both serological testing and NAT has considerably
reduced the risk of viral transmission by blood transfu-
sion [28-30].
HIV and HCV
Surveillance studies in Europe and in the U.S. have docu-
mented a significant reduction in the risk of HCV and HIV
transmission through blood products over the last three
decades [30-32]. In the mid 1980's, anti-HIV serological
testing was introduced, followed a few years later by sim-
ilar approaches for HCV. In 1995, the European plasma
fractionating industry introduced viral NAT as a method
to further ensure the integrity of virus interdiction and
between 1998 and 2001, the new screening methods were
widely introduced in many additional countries[31,33].
The implementation of viral NAT testing has greatly
helped to reduce the residual risk of viral transmission
during the 'window period' by reducing the time for effec-
tive detection from 22 days (with solely serological test-
ing) to 11 days for HIV and from 70 to 10 days for HCV
[30,34]. As a consequence, the estimated risk for HIV
transmission to date is between 0.14 – 1.1 and for HCV
between 0.10 – 2.33 per million units transfused[30,35-
40].
As shown in a recent study assessing the risks of transfu-
sion-mediated HIV and HCV infections between 1999
and 2003[26], the benefits of NAT testing over antibody
testing were confirmed by showing that one out of
230,000 donations tested positive for HCV RNA but not
for anti-HCV antibodies. For HIV, with an apparently
shorter window period, one out of 3.1 million donations
was RNA positive but antibody negative. However, the
observed NAT detection rates and its relative benefits can
vary widely between sites. For instance, in Europe only 54
anti-HCV antibody negative, HCV RNA positive samples
were identified among 58 million donations tested (NAT
yield: 0.93 NAT reactive sample per million antibody neg-
ative donations) compared to North America (NAT yield:
3.92/million donations) or the Pacific area (NAT yield:
2.37/million donations)[33]. In addition, NAT detection
rates may be affected by viral sequence polymorphisms
and next generation NAT tests need to be designed to
effectively cope with increasing global viral diversity, espe-
cially for highly variable pathogens such as HIV and
HCV[41].
HBV
The risk of TT HBV infection has been continuously
reduced since the introduction of the hepatitis B surface
antigen (HbsAg) testing in the early 1970's, but with more
than 300 million individuals infected world wide, HBV
remains a considerable risk for TT infection. HBV surface
antigen (HbsAg), the main screening target, is routinely
included in the donor screening, but fails to detect the
presence of HBV during the 'window period'. A number of
countries have also added the testing for antibodies
directed against the HBV core protein (anti-Hbc) to the
standard screening in an attempt to detect chronic virus
carriers with low-level viremia who may not have detecta-
ble HBsAg levels. Today, the residual risk of TT HBV infec-
tion varies between 0.75 per million blood donations in
Australia, 3.6 – 8.5 in the USA and Canada, 0.91 – 8.7 in
Northern Europe, 7.5 – 13.9 in Southern Europe up to
200 per million donations in Hong Kong, largely reflect-
ing the global epidemiology of HBV[33]. Even though at
present, no regulations for mandatory testing of blood
components for HBV NAT exist, a number of countries
with low HBV prevalence have implemented HBV NAT
testing in plasma pools[33,35,42,43]. However, there is
no evidence, so far, that pooled testing with HBV NAT is
superior to the most sensitive tests for HBsAg.
The kinetics of viral antigen and antibody appearance dur-
ing HBV infection create two different window periods in
which one or the other test may fail: the "early acute
phase", when serological markers are still negative and the
"late chronic phase" when HBsAg may become gradually
undetectable, although infectivity remains [44,45]. Thus,
the effective immunological window period could be
longer than what is generally considered (median of 59
days)[45-47]. NAT could potentially identify some of
these cases and may also be of particular benefit in the
detection of HBV DNA in "occult HBV infection", where
HBV DNA is present in the plasma in the absence of
detectable HBsAg and variable presence of anti-HBc and/
or anti-HBs antibodies [48,49]. In addition, in some
cases, infection by HBV mutants that affect the surface
antigen conformation may result in failure to detect HBV
infection by routine diagnostic assays [50-52]. Even
though HBV NAT could detect these cases, higher levels of
sensitivity for NAT may be necessary to cope with the
characteristically low level viremia (< 500 IU/ml) seen in
occult HBV infection [53-56].
West Nile Virus
West Nile virus (WNV), a mosquito-borne RNA virus of
the flavivirus family, is an emerging TT agent with poten-
tial future importance for the North American continent.
WNV was first isolated in samples obtained in 1937 from
patients in Uganda were the virus is endemic and more
recently appeared in New York City in 1999. A total of
4,200 cases of WNV infections were reported to the Center
for Disease Control and Prevention (CDC) in 2002, and
by 2003 the number had risen to 9,858 cases including
262 deaths (a 2.66% reported mortality rate). In 2004 and
2005, the reported cases declined (2,282 and 2,949 casesJournal of Translational Medicine 2007, 5:25 http://www.translational-medicine.com/content/5/1/25
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with 77 and 116 fatalities, respectively) [57]. While most
(80%) WNV infections occur asymptomatically or with
only mild flu-like symptoms without sequelae, in 0.6% of
infections, neuro-invasive disease culminating in fatal
meningitis or encephalitis can occur, especially in
immune-compromised and elderly subjects[58]. In 2002,
23 cases of transfusion- and four cases of organ-transmit-
ted WNV infection were reported and WNV-specific NAT
testing was implemented as routine screening in the USA
in 2003 [59-62]. Of 27.2 million donations screened,
1,039 viremic donations were identified, with many sam-
ples showing low-level viremia [63]. Therefore, WNV NAT
is usually performed at the single-donation level in loca-
tions and periods with high incidence of infection[64,65].
No TT WNV case has been described so far in Europe, nor
did any blood donation test positive for WNV RNA
among 62,000 tested samples in the Netherlands[66]. In
fact, WNV prevalence is quite infrequent in Europe, prob-
ably as a result of viral strain differences, herd immunity,
and a relative absence of mosquitoes that can transmit the
virus to humans.
Aside from HIV, HCV, HBV and WNV, a number of other
viral infections transmitted by transfusion of blood prod-
ucts have been described, even though not all have been
associated with clinical manifestation. Human T cell lym-
photropic viruses I and II (HTLV-I/II) are associated with
adult T cell leukemia and HTLV-associated myelopathy/
tropical spastic paraparesis[67]. Both retroviruses have
also been attributed a role in the increased risk for devel-
oping severe asthma, respiratory and urinary tract infec-
tions, uveitis and dermatitis [68-71]. The global
epidemiology of HTLV varies widely with prevalence rates
up to 10% in certain areas in Japan, and up to 5–6 % in
countries of the Caribbean, the Sub-Saharan Africa, and
areas in the Middle East and South America[71]. Transfu-
sion-associated transmission of HTLV-I/II occurs through
cellular components only and infectivity declines with
component storage, particularly after 10 days [72]. The
risk of HTLV transmission in the U.S. is very low (1 in 3
million) and cases of HTLV-related disease after transfu-
sion transmission are rare[30].
The transfusion-associated transmission of human herpes
viruses, including cytomegalovirus (CMV) and human
herpesvirus 8 [HHV-8, also known as Kaposi's Sarcoma-
associated herpesvirus] have been described and can pose
significant threats, especially to immunocompromised
subjects. Like all human herpes viruses, both are cell-asso-
ciated pathogens and cellular components are thus the
main compartment for their transmission by transfused
blood products. Recommendations for the control of
CMV transmission to susceptible groups have been estab-
lished and patients at increased risk of CMV disease
should only receive CMV-seronegative and/or leucore-
duced products, the latter of which has been shown to
reduce the risk of CMV transmission considerably [73-76]
HHV8, a human gamma-herpesvirus is the causative agent
of Kaposi's Sarcoma, and the probable cause of multicen-
tric Castleman's disease and primary effusion lym-
phoma[77]. Although normally transmitted through
saliva or sexual contact, there is evidence now that HHV-
8 can be transmitted via blood transfusion or solid organ
transplantation [78-80]. Despite this evidence of success-
ful blood-borne transmission of HHV-8, no data exist yet
that link TT HHV-8 transmission to HHV-8-associated dis-
eases in immunocompetent subjects[81,82].
Parvovirus B19 (PV-B19) is a non-enveloped erythrovirus
which infects hematopoietic cells. In healthy individuals,
PV-B19 infection via the respiratory route leads to ery-
thema infectiosum (Fifth disease), usually a mild and self-
limited childhood disease that manifest itself in adults
with fever, rash, myalgia, and arthropathy. Pregnant
women can transmit the infection intra-uterine with sub-
sequent fetal heart failure and hydrops fetalis. Transfusion
transmissions of PV-B19 with mild and non-life-threaten-
ing symptoms, even in immuno-compromised patients,
have been reported in several studies and epidemiologic
analyses have found B19 to be a recurring contaminant of
blood products [83-85]. Since the virus lacks an envelope,
it is resistant to most virus inactivation methods (solvent/
detergent method, heat inactivation or methylene
blue)[83,84,86]. In Europe, plasma pools used for pro-
duction of anti-D immunoglobulin must not exceed 104
IU of B19 per milliliter and novel, PCR-based detection
and quantification kits have been developed to this end in
the last few years [87].
Two viruses generally associated with fecal-oral transmis-
sion, hepatitis A virus (HAV) and E virus (HEV), have
been shown to be at least occasionally transmissible via
blood transfusion. Both pathogens are non-enveloped
RNA viruses with a low prevalence in developed countries
that have advanced environmental hygiene; a vaccine is
available for HAV. However, only a few HAV and HEV
transfusion-transmissions have been reported, with only
mild liver disease as a result [88-91].
There are some other viral agents such as HGV (hepatitis
G virus, also known as GB virus type C), TT-virus and SEN
virus that have been shown to be transmissible by blood
products[92,93]. In a study conducted in Germany in
2004, 1.6% of 25,000 donations screened were found to
be HGV RNA positive[94]. Similarly, the prevalence of
TTV among healthy blood donors is widespread, espe-
cially in Asia (14–36%) [95,96] while the prevalence of
SEN-V in healthy individuals ranges from 1.8% (USA) up
to 22% in Japan[97]. However, no report exists that linksJournal of Translational Medicine 2007, 5:25 http://www.translational-medicine.com/content/5/1/25
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the transfusion-associated transmission of any of these
viruses with clinical symptoms and no procedures to pro-
tect the blood supply from these pathogens have been
implemented.
Aside from the above viral pathogens for which TT related
infections have been more or less well documented, there
are a number of other potential TT viral threats for which
comparable information is missing. Among these, the
coronavirus of the severe acute respiratory syndrome
(SARS-CoV) or the H5N1 influenza A virus (avian flu)
both seem to have primarily respiratory modes of trans-
mission, but evidence of viremia suggests caution and
blood-borne transmission has yet to be conclusively ruled
out. Especially for SARS-CoV, concerns about potential
risk for transfusion transmission led to global implemen-
tation of temporary precautionary measures [98]. For rel-
ative risk evaluation it will be useful to consider the length
of asymptomatic viremic stages in the infected individual,
as viruses with only very short viremic episodes along with
low levels of viremia may represent relatively moderate
risks for TTI, as is the case for WNV.
Parasites
Parasites are common infectious agents worldwide, and
several protozoans have been shown to be transmitted via
blood transfusion[99]. Malaria is endemic in tropical and
sub-tropical regions of Africa with up to 300 million infec-
tions and one million deaths annually[100]. It is caused
by one of the four species of Plasmodium, (falciparum,
vivax,  malariae  and  oval) which are mosquito-borne
intraerythrocytic parasites that infect liver and red blood
cells (RBC) causing periodic episodes of fever and flu-like
symptoms, along with massive lysis of erythrocytes. The
risk of TT malaria differs widely between low-endemic
countries, where the infection is "imported" from outside
(e.g. travel to or immigration of individuals from highly
endemic regions) and regions of high prevalence of plas-
modium infection in the general population. For the lat-
ter, only limited data are available, with one report from
Benin showing one third of the screened blood donors to
harbor  Plasmodium falciparum trophozoites and poten-
tially be able to transmit the pathogen by blood prod-
ucts[101]. The risk in low-endemic areas is introduced
from either travelers to, or immigrants from, high
endemic areas[99,102-104]; the latter are usually individ-
uals with a protective immune status who, after many
years of infection, can still harbor parasites. Nevertheless,
the risk of transfusion-transmitted malaria in low-
endemic areas like Europe and the U.S. is low, with only
one in 3–4 million units transfused being potentially
infectious[105,106]. In some European countries, as well
as the U.S., current strategies to prevent TT malaria are
based on risk group assessment and include donor defer-
ral for 4–12 months for visitors from low-endemic areas
to high-endemic countries, and 3–5 years [or perma-
nently] for donors with a history of residency in an
endemic area[105,107,108]. However, this deferral policy
leads to an extensive, and for some countries unafforda-
ble, loss of blood donations; this reason is why combined
travel-based risk assessment and serological screening
tests (enzyme immunoassays, EIA or immunofluorescent
antibody test, IFAT) have been introduced in a number of
countries [107,109-111].
Trypanosoma cruzi, the etiologic agent of Chagas disease
(CD), is endemic in Central and South America and parts
of Mexico and acute infection can be accompanied with
acute symptoms like fever, lymphoadenomegaly or
hepato- and spleenomegaly. After 10–40 years, 20–30%
of infected patients present with serious organ enlarge-
ments (cardiomegaly and occasionally mega-esophagus).
Individuals from endemic areas may be chronic carriers of
the parasite and are potentially at risk of transmitting the
parasite via transfusion of their blood. Although a study
performed in the U.S. found a noticeable seroprevalence
rate of 0.12–0.20% among such risk donors, blood-borne
T. cruzi infections are infrequent in North America, with
only 7 reported cases. Transfusion cases are well-known in
Mexico, Central and South America[112,113]. In many of
these countries, serological testing is performed and posi-
tive donors are deferred[114]; With the recent licensure of
a blood donor screening test, such testing will shortly start
in the US.
Other parasites that have been implicated in transfusion-
associated transmission are tick-borne pathogens, of
which Babesia microti, the etiologic agent of babesiosis, is
the most frequent transfusion-transmitted parasite. Babe-
sia microti is transmitted by Ixodes ticks and can lead to
severe complications including hemolytic anemia, throm-
bocytopenia and death, especially when transmitted to an
immunocompromised or asplenic subject. There are only
few studies regarding transfusion-transmitted babesiosis,
including some reporting fatal disease outcome[113], but
more than 60 cases are known in the US. Since babesia is
an intra-erythrocytic microbe, leucoreduction is an inef-
fective approach to reduce transmission risk and, given
the absence of appropriate serological assays, poses a
blood safety risk. Leishmania donovani, transmitted prima-
rily by the bite of infected sand flies has also been shown
to be transmitted by blood and cause clinical disease in
newborns and immunosuppressed subjects. However,
these cases appear to be restricted to highly endemic areas
such as the Middle East and do not pose significant risks
in other parts of the world [115]. Nevertheless, individu-
als returning to the U.S. from combat zones in Iraq are
currently deferred for one year. Aside from parasites, other
tick-borne agents such as the two bacteria Anaplasma
phagocytophilum and Rickettsia rickettsii have been rarelyJournal of Translational Medicine 2007, 5:25 http://www.translational-medicine.com/content/5/1/25
Page 7 of 11
(page number not for citation purposes)
found in blood products although most TT tick-borne
infections have been largely confined to the Northeastern
U.S. and one case of TT babesia infection in Japan
[116,117].
Human prion disease
Variant CJD (vCJD) is the human form of the bovine
spongiform encephalitis [BSE]. However, unlike classic
Creutzfeldt-Jacob disease (CJD), variant CJD (vCJD) pri-
marily affects people under 50 years of age and is likely to
have been transmitted by consuming tissues from BSE-
infected animals. Although initially not considered
blood-borne, prion diseases have been shown in animal
models to be transmissiable by blood products [118].
While evidence for blood-borne transmission of classic
CJD is still lacking, three cases of transfusion-transmitted
vCJD have been reported in the UK [119-122]. In all three
reports, the blood donors developed clinical-apparent
vCJD after blood donation. Two of the recipients showed
signs of clinical disease whereas the third patient was
asymptomatic, but had detectable prions at the time of
death (from an unrelated cause). Notably, all three
infected patients received non-leucodepleted red blood
cells despite the fact that, to date, no TT vCJD case has
been associated with the use of plasma products. One
important factor to estimate the risk that TT prion diseases
may pose in the future is the potentially prolonged pre-
clinical carrier state which can last for decades and thus
represents a significant risk for transfusion-medicine, at
least in regions such as England, Ireland and France where
many cases of vCJD have been reported [123]. As a coun-
termeasure, France and the U.K. have adopted the practice
to decline individuals who have received a transfusion of
any blood component since 1980 indefinitely. Similarly
in the U.S. donors with a history of extended residence in
the U.K. or Europe, or a history of transfusion in the U.K.,
are permanently refused.
Pathogen inactivation
The concept of pathogen inactivation in blood compo-
nents is to reduce the residual risk of known pathogens
and to effectively eliminate new, yet unknown pathogens.
However, the different approaches should increase the
blood safety without compromising the product efficacy
or causing adverse effects, as toxic or mutagenic chemicals
may be used in the process. While a number of pathogen
reduction methods are employed in Europe, none of them
are currently available in the U.S. The choice of a patho-
gen reduction approach depends on whether it is used to
treat components for transfusion such as RBC, PLT and
plasma, or for products manufactured from the plasma. In
Europe, two distinct methods, methylene blue (MB) and
solvent-detergent (SD) are currently employed for the
treatment of plasma intended for transfusion. MB is a
phenothiazine colorant that inactivates most viruses and
bacteria after exposure to visible light. While it has the
advantage of being useful for single plasma units, its inef-
fectiveness against intracellular pathogens and probable
interaction with coagulation factors considerably reduce
its efficacy[124]. The SD approach acts by disrupting the
envelope proteins of targeted pathogens, thus compro-
mising the integrity of the pathogen and rendering it non-
infectious. This approach is used on small pools of
plasma. The limitation of this technique is that it is not
active against non-enveloped pathogens, and that levels
of coagulation factors such as protein S may be decreased
significantly by some of the SD treatment methods
[125,126].
Amotosalen HCL (S-59) is a synthetic psoralen which,
when combined with exposure to ultraviolet A [UVA]
light, causes a permanent crosslink in bacterial and viral
nucleic acid chains, thereby stopping pathogen replica-
tion[127]. The photochemical treatment (PCT) with amo-
tosalen and UVA light can be used for FFP and platelets. A
commercial product based on this approach is the INTER-
CEPT system, which has been introduced into clinical
practice in Europe a few years ago and has completed
phase III trials in the USA [28]. Extensive studies have
shown that this approach is effective against all pathogens
that are currently screened for, including enveloped and
non-enveloped viruses, bacteria (Gram-positive and -neg-
ative) and protozoans (T. cruzi and  Plasmodium falci-
parum) [128-131]. However, a large controlled study has
indicated that PCT may have negative effects on the func-
tionality of platelets as transfusions using treated platelet
preparations had to be repeated in shorter intervals than
when using untreated platelet preparations [132]. Aside
from these approaches to pathogen reduction in platelet
preparations, at least three techniques for pathogen inac-
tivation in RBC are currently under development: S-303, a
synthetic alkylating agent, (a compound of the frangible
anchor-linked effectors [FRALE] class) capable of disrupt-
ing pathogen RNA or DNA[133]; Inactine, a binary ethyl-
eneimine that binds to nucleic acids resulting in the
inhibition of pathogen replication [134-137]; and ribofla-
vin [vitamin B2], a naturally occurring nutrient [138-143].
Even though some of these agents have entered phase III
clinical trials none of them have been officially approved
at the time this review was written. These approaches, as
well as newly developed ones, will need to show convinc-
ingly that they successfully eliminate targeted pathogens
while maintaining blood product quality. In addition,
possible limitations, such as high costs, long-term side
effects of some additives and inability to inactivate certain
pathogens like spore-forming bacteria will need to be
overcome to ensure pathogen-free blood products on a
large scale and at affordable prices.Journal of Translational Medicine 2007, 5:25 http://www.translational-medicine.com/content/5/1/25
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Conclusion
The general public may be idealistic in their belief that
risk-free blood products are achievable in today's world.
In fact, the threat of infectious agents entering the blood
supply is not static and may evolve as new pathogens
emerge or as old ones change their epidemiological pat-
tern. Nevertheless, the goal of a safe and affordable blood
supply that can meet the growing global demands may be
reached by the coordinated optimization of each step in
the transfusion chain, including the careful consideration
of donor eligibility criteria, adherence to rigorous rules
during donation, processing and storage, the optimal
implementation of available screening tests, the use of
suitable pathogen inactivation methods and finally the
vigilance of prudent physicians, who evaluate the neces-
sity of each transfusion. Efforts invested in providing low-
est possible risk blood products need to be matched by
the diligence of physicians administering the transfusions
who need to report adverse consequences of blood trans-
fusions. Hence, national haemovigilance systems linked
to an international network are becoming indispensable
elements of blood product safety and quality. Combined
with the development and implementation of sensitive
and affordable detection and inactivation approaches,
these measures can make blood transfusion a safer form
of therapy even in places where the risks to date have to be
considered significant [5,6,144,145].
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